SAN DIEGO & SALT LAKE CITY--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 12, 2020 and June 16, 2020. Chembio develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases.
If you suffered a loss as a result of Chembio's misconduct, click here.
Chembio Diagnostics, Inc. (CEMI) Accused of Misleading Shareholders
According to the complaint, in March 2020, Chembio entered into a strategic partnership to begin the development of a diagnostic test for the detection of the COVID-19 virus and IgM and IgG antibodies. Throughout the relevant period, Chembio touted that its antibody test provides high sensitivity and specificity, and was 100% accurate. As a result of these positive representations, Chembio's stock price soared from a closing price of $5.12 per share on March 31, 2020 to a closing price of $15.54 per share on April 24, 2020. Chembio took advantage of the stock's trading success and closed the public offering of 2.6 million shares at $11.75 per share for gross proceeds of approximately $30.8 million on May 11, 2020. Despite Chembio's purported success, on June 17, 2020, the Company disclosed that the FDA had revoked its Emergency Use Authorization of Chembio's antibody test "due to performance concerns with the accuracy of the test." On this news, Chembio's shares fell $6.04, or 60%, to close at $3.89 per share.
If you purchased Chembio Diagnostics, Inc. (CEMI) securities between March 12, 2020 and June 16, 2020, you have until August 17, 2020, to ask the court to be appointed lead plaintiff for the class.
Want to be notified if a class action against Chembio settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.